Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia - Full Text View

Purpose

The study is a cross sectional, epidemiology study of disease severity for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in four geographic regions in Australia (Illawarra, Sutherland, Hunter Urban and Hunter Rural).

Condition

Ankylosing Spondylitis
Psoriatic Arthritis
Rheumatoid Arthritis

Genetics Home Reference related topics:

ankylosing spondylitis

MedlinePlus related topics:

Ankylosing Spondylitis Rheumatoid Arthritis

U.S. FDA Resources

Study Type:	Observational
Study Design:	Other, Cross-Sectional

Official Title:	Australian Descriptive Epidemiology Study of Severity of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) and Exposure to Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs)

Further study details as provided by Wyeth:

Primary Outcome Measures:

Proportion of rheumatoid arthritis/psoriatic arthritis/ankylosing spondylitis patients in defined disease severity categories [ Time Frame: Single visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Proportion of patients exposed to biological disease modifying antirheumatic drugs [ Time Frame: Single visit ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	560
Study Start Date:	September 2008
Estimated Study Completion Date:	March 2009
Estimated Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

Groups/Cohorts

1

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Primary care

Criteria

Inclusion criteria include:

Adult patients with a diagnosis of rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who have visited a primary care centre within one of the specified catchment areas for their condition within the last 24 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00751387

Contacts


Contact: Trial Manager		clintrialparticipation@wyeth.com

Sponsors and Collaborators

Wyeth

Investigators


Study Director:	Medical Monitor	Wyeth

More Information

Responsible Party:	Wyeth ( Wyeth (Registry Contact: Clinical Trial Registry Specialist) )
Study ID Numbers:	0881X1-4519
First Received:	September 11, 2008
Last Updated:	September 11, 2008
ClinicalTrials.gov Identifier:	NCT00751387
Health Authority:	Australia: Human Research Ethics Committee

Study placed in the following topic categories:

Spinal Diseases

Autoimmune Diseases

Skin Diseases

Arthritis, Psoriatic

Spondylarthropathy

Joint Diseases

Arthritis, Rheumatoid

Rheumatic Diseases

Bone Diseases

Musculoskeletal Diseases

Psoriasis

Arthritis

Connective Tissue Diseases

Spondylitis, Ankylosing

Skin Diseases, Papulosquamous

Spondylarthritis

Spondylitis

Ankylosis

Spondylarthropathies

Additional relevant MeSH terms:

Immune System Diseases

Infection

Bone Diseases, Infectious

ClinicalTrials.gov processed this record on October 06, 2008

Sponsored by:	Wyeth
Information provided by:	Wyeth
ClinicalTrials.gov Identifier:	NCT00751387